Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.04 USD

83.04
5,653,121

+0.83 (1.01%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $83.05 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study

Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.

    Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

    Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

      Arpita Dutt headshot

      Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

      Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

        Mylan Receives Tentative Approval from FDA for HIV Therapy

        Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).

          Kevin Cook headshot

          Biotech Bull Making a Comeback

          A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor

            Arpita Dutt headshot

            Why Biotech Stock Gilead (GILD) Could Be a Value Trap

            Gilead's (GILD) valuation looks compelling but is the company really poised for

              Arpita Dutt headshot

              Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

              The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

                Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

                At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.

                  Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

                  We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal

                    Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.

                      Arpita Dutt headshot

                      Is This the Right Time to Invest in Biotech Stocks?

                      The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?

                        Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                        Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                          Sweta Killa headshot

                          Biotech ETF (BBH) Hits New 52-Week High

                          This biotech ETF hit a new 52-week high. Are more gains in store for this ETF?

                            Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow

                            Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.

                              Arpita Dutt headshot

                              Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

                              Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

                                Arpita Dutt headshot

                                Pricing to Remain Pharma Headline Risk in 2017

                                Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.

                                  United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

                                  United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

                                    While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

                                      Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

                                      Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

                                        David Bartosiak headshot

                                        Five Major Myths about Options Trading

                                        These are the five biggest myths about options trading

                                          Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)

                                          Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

                                            Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

                                              Gilead (GILD) Announces Data on Combination Therapy for HIV

                                              Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

                                                The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                                The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                                  Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

                                                  The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.